• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA Gears Up for Raw Data Review Pilot Program

EMA Gears Up for Raw Data Review Pilot Program

July 18, 2022

The European Medicines Agency (EMA) is inviting sponsors to apply for participation in a pilot program that will assess the benefits of submitting and assessing “raw data” during reviews by the Committee for Medicinal Products for Human Use (CHMP).

CHMP’s current review process primarily involves the assessment of data in clinical summaries and information in trial reports, which come in a format that “does not directly allow disaggregation or any other form of further analysis,” the EMA said. But for some regulatory procedures, it may be beneficial to have access to raw data — individual, electronically formatted patient data from trials that are directly available for reanalysis, additional analysis and visualization — during a CHMP review, the agency said.

“Access to raw [data] can assist regulators in understanding the submitted evidence and therefore inform the regulatory decisions on the benefit-risk balance of the product,” the EMA said in a document outlining the pilot. The agency noted that it reflected on previous reviews involving raw data and found a number of benefits, including an improved understanding of study results that informed approvals, fewer questions for applicants and optimized inspections.

The pilot program will kick off in September, when participants in the program will be allowed to submit raw data as part of their initial marketing authorization applications and postauthorization applications. The pilot will run for up to two years and take approximately 10 applications.

To apply for the pilot, email rawdatapilot@ema.europa.eu.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 13Sep

    Trial Master File Inspection Readiness: From Chaos to Calm

  • 14Sep

    Omnichannel Engagement: Are You Digitally Ready? 

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 16Oct

    WCG MAGI's Clinical Research Conference 2022 West

  • 16Nov

    17th Annual FDA Inspections Summit

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Options-360x240.png

    Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

  • SurveywBlueBackground-360x240.png

    New Study Shows Trends in Funding, Racial Balance Amidst COVID-19

  • Complexity-360x240.png

    Rising Trial Complexities Create More Payment Problems, Frustrations for Sites

  • Challenge-360x240.png

    BYOD Trials Growing in Popularity, But Unique Tech Challenges Remain

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing